Bristol-Myers Squibb BMY
BMY is overpaying ~$30B for Celgene's risky pipeline, betting on 10 blockbusters in 8 years vs 3 in 15; shareholders should vote against and unlock 900bps of standalone margin upside.
Thesis
Starboard opposes Bristol-Myers' proposed $91 billion acquisition of Celgene, arguing the deal abandons BMY's successful 'String of Pearls' strategy and transfers enormous pipeline risk to shareholders. Starboard calculates BMY is actually paying ~$30 billion for Celgene's pipeline (not the ~$15 billion management implies) once synergies are correctly allocated, and the base case requires Celgene to deliver 10 blockbusters in 8 years versus just 3 in the past 15. With REVLIMID facing 2026 loss-of-exclusivity and five pipeline products still unidentified, the deal destroys value in most realistic scenarios — a single product failure could wipe out $46B. Instead, Starboard proposes a standalone path: expanding adjusted EBITDA margins from 36% to 45% (a 900bps improvement following Amgen's 2014-2018 blueprint), continuing disciplined small-scale M&A, and deploying ~$37B of cumulative free cash flow over five years. The closing recommendation: vote AGAINST the Celgene transaction.
SCQA
Bristol-Myers is a large-cap biopharma that since 2007 has grown via a disciplined 'String of Pearls' strategy — small acquisitions, licenses, and partnerships anchored by its Opdivo and Eliquis franchises.
Management is now proposing a $91B mega-merger with Celgene that defies that strategy, embeds unprecedented pipeline assumptions, and appears rushed by an arbitrary deadline — possibly as a defensive anti-takeover move.
Shareholders should vote AGAINST the Celgene acquisition and instead back a standalone path: continue 'String of Pearls' and execute a 900bps EBITDA margin improvement plan modeled on Amgen 2014-2018.
Standalone BMY can lift adjusted EBITDA margins from 36% to 45% (peer average 48%), deploy ~$37B of unlevered free cash flow over five years, and avoid up to $46B of potential value destruction from pipeline misses.
The three reasons
- 1
BMY is actually paying ~$30B for Celgene's pipeline, not ~$15B as implied
- 2
Deal requires 10 blockbusters in 8 years vs Celgene's 3 in the past 15
- 3
Standalone BMY has 900bps of EBITDA margin upside, following the Amgen blueprint
Primary demands
- Vote AGAINST the proposed $91B acquisition of Celgene
- Remain a standalone company and continue the 'String of Pearls' strategy
- Execute a 900bps EBITDA margin improvement program (COGS, SG&A, R&D)
- Deploy ~$37B of cumulative unlevered free cash flow into disciplined in-licenses, partnerships, and small acquisitions
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Amgen 2014-2018 margin transformation (+1,500bps operating margin)
- Bristol-Myers 'String of Pearls' legacy (PDL BioPharma 2008, Medarex 2009, Cardioxyl 2015, Flexus 2015, IFM 2017)
- Pfizer/Warner-Lambert 1999
- GlaxoWellcome/SmithKline Beecham 2000
- Sanofi/Aventis 2004
- Actavis/Allergan 2014
- Takeda/Shire 2018
Notable slides (6)
Notes
Filed as Exhibit 1 to a DFAN14A dissident proxy filing (hence 'ex1todfan14a' in filename), dated March 18, 2019 — Starboard's campaign opposing BMY's $91B acquisition of Celgene. Heavy use of management's own quotes (Jim Cornelius on 'String of Pearls'; Caforio on standalone strength) to expose strategic inconsistency. Signature contrarian framing: '10 blockbusters in 8 years vs 3 in 15.' Amgen margin-transformation precedent is the affirmative blueprint. 197 pages is unusually long even for an activist deck — effectively a dossier rather than a presentation.